Navigation Links
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
Date:9/19/2013

SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

The Phase 1 clinical program in healthy subjects established dosing regimens that were well tolerated and associated with high levels of PDE10 target engagement in the brain, supporting advancement of OMS824 into patient-directed trials. In this Phase 2 clinical trial, OMS824 will be administered at various dose levels for two weeks to patients whose antipsychotic medications have been temporarily discontinued or who continue their usual antipsychotic regimen in order to assess the effects of OMS824 as monotherapy and in combination with antipsychotic medications. A variety of cognitive tests will be assessed, although the relatively small size of this trial will limit the ability to detect treatment effects, if present.  The safety and any efficacy findings in this trial are planned for use in determining appropriate dosing regimens and selecting endpoints for subsequent Phase 2 and Phase 3 clinical trials in schizophrenia. Those trials are expected to evaluate OMS824 in schizophrenic patients who are psychiatrically stable with cognitive impairment, in patients with acute exacerbation of symptoms, and/or in patients with inadequate response to antipsychotic medications.

"We are excited to begin assessing OMS824 in patients suffering with schizophrenia," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "This Phase 2 trial will provide us with important info
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Reports Additional Positive Results from OMS824 Program
2. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
3. Omeros to Present at the Stifel Healthcare Conference 2013
4. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
5. Omeros Corporation Reports Second Quarter 2013 Financial Results
6. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
7. Omeros Submits New Drug Application to U.S. FDA for OMS302
8. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
9. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
10. Omeros Corporation Reports First Quarter 2013 Financial Results
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... -- Pixcelldata, the innovative Irish developer of ... major new deal with Dutch based eX-Path, global providers ... Marius Nap . The announcement was ... Pathology which is taking placing between August 30th and ... where Pixcelldata will demonstrate its innovative solution. ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
(Date:8/30/2014)... According to the latest review on DailyGossip.org, this is ... skin health. It seems that the method is so popular ... 138,000 patients from all over the world. , The ... method will not only eliminate acne forever, but will also ... this program unique among other methods of curing candida is ...
(Date:8/30/2014)... Capital Region, NY (PRWEB) August 31, 2014 ... the largest and fastest growing union in New York ... bringing good, middle-class healthcare jobs and the best quality ... regions. , In recent years, thousands of healthcare ... for themselves and their families by becoming members of ...
(Date:8/30/2014)... UWDress.com, a distinguished wedding dress supplier, has gained ... of fashionable outfits. Recently, the company has unveiled its beautiful ... autumn special offer, all these brand new products are provided ... “We are excited to unveil the new and trendy bridesmaid ... products are available at low prices now. The purpose of ...
(Date:8/30/2014)... San Diego, CA (PRWEB) August 30, 2014 ... Rebecca Doherty upheld a decision that requires Takeda Pharmaceutical ... billion in punitive damages for claims that the drugmakers ... with the diabetes medication Actos. The case, Allen v. ... the U.S. District Court, Western District of Louisiana (Lafayette).* ...
(Date:8/30/2014)... United Theological Seminary is pleased to announce the launch ... Theological Studies (MTS). , This degree, which ... who wish to pursue further academic study of religion (Ph.D.) ... Church and community. Previously, students needed to be on campus ... from any location where there is an internet connection. ...
Breaking Medicine News(10 mins):Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 3Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 4Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2
... GUANGZHOU, China, July 17 /Xinhua-PRNewswire/ -- China ... or "the Company"),a leading distributor and developer ... (TCMs), nutritional and dietary supplements,medical devices, and ... China,(PRC), announced today that it obtained a ...
... 17 Fresh Harvest Products,Inc. (OTC Bulletin Board: ... its long standing commitment to providing consumers with ... new initiative to,build natural and organic brands and ... Harvest brands,through our network., "We believe that ...
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices worldwide has announced today that it will,highlight ... well as,unveil three new units and reagents at ... conference. The conference will be attended,by Mr. Jie ...
... Calif., July 17 Cardica, Inc.,(Nasdaq: CRDC ... to the,position of vice president, operations. Mr. Bauer ... operations and manufacturing experience to,Cardica from large healthcare ... operations experience and his continuous drive to,improve quality ...
... 2, 2009 -, LAVAL, QC, July 17 /PRNewswire-FirstCall/ ... the response that it submitted to the,U.S. Food and ... analysis of existing data as suggested by the Agency, ... action date assigned by the,FDA under the Prescription Drug ...
... Ceremonies for the 23rd Annual Great Sports,Legends Dinner to Benefit The Buoniconti ... ... NEW YORK, July 17 Sports luminaries and philanthropy,icons will be recognized ... September 22, at New York,s Waldorf=Astoria,Hotel. This year, Bob Costas has been ...
Cached Medicine News:Health News:China Medicine Corporation Obtains Australian Patent for rADTZ 2Health News:China Medicine Corporation Obtains Australian Patent for rADTZ 3Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 2Health News:Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 3Health News:Cardica Names Frederick Bauer Vice President of Operations 2Health News:Cardica Names Frederick Bauer Vice President of Operations 3Health News:FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response 2Health News:Sports Luminaries Andre Agassi, Jerry Rice, Scottie Pippen, Helio Castrovenes, Richard 'Goose' Gossage Among Those Named 2008 'Great Sports Legends' 2Health News:Sports Luminaries Andre Agassi, Jerry Rice, Scottie Pippen, Helio Castrovenes, Richard 'Goose' Gossage Among Those Named 2008 'Great Sports Legends' 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: